Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Genetic Engineering and Biotechnology Institute (GMBE) originates from the Biology Department which was founded in 1983 as a part of TÜBðTAK Gebze Research Center’s Fundamental Sciences Research Institute in order to conduct basic and applied original researches in molecular biology. The Biology Department was then transformed to Genetic Engineering and Biotechnology Institute and affiliated to Marmara Research Center in 1992. The vision is to be one of the leading research centers of the world, that produce original knowledge and technology in the field of genetic engineering and biotechnology.
The institute conducts researches and develops technologies in the field of Genetic Engineering and Biotechnology with high added value by taking into consideration the developments in the world and the needs of the public and industrial sectors in Turkey. Its projects and industrial services cover the following areas: Animal Biotechnology, Medical Biotechnology, Enzyme and Fermentation Technologies.
Animal Biotechnology Strategic Business conducts high-quality basic and applied research activities related to animal reproduction (IVF, nuclear transfer, ICSI) as well as production of transgenic animals to investigate molecular mechanisms of human and animal diseases. Utilization of animal bio-banks (embryo, cell, DNA) established to improve breeds and functional characterization of genes by using genomic/proteomic approaches are the future-planned working areas of the unit.
Medical Biotechnology Strategic Business Unit has both the technological infrastructure and the expert research personnel leading advanced and innovative R & D activities. The Unit provides high-quality solutions and pursues projects for both the industry and public organizations to meet national needs with its know-how and technological background. Currently, there are 14 Ph.D. researchers and 2 technicians in the Medical Biotechnology Strategic Unit.
Medical Biotechnology Strategic Business Unit is composed of 4 laboratories: Bionanotechnology Laboratory, Molecular Cellular Biology Laboratory, Immunogenetic Laboratory, Vaccine Technology Laboratory.
Basic activities of Enzyme and Microbial Biotechnology strategic business unit include screening of microorganisms from different environments for industrial enzymes, isolation and identification of these microorganisms, optimization of the process technologies for important enzymes, prufication, immobilization and formulation of the products for industry. Enzyme and Microbial Biotechnology strategic business unit has two laboratories; Enzyme and Fermentation Technology Laboratory, Enzyme and Microorganism Genetics Laboratory. Plant Biotechnology Strategic Business Unit performs basic and applied R&D activities along with modern applications in its filed in order to prevent agricultural crop losses, to obtain plants resistant to stress conditions and to identify genetic resources on the basis of genes and proteins, in accordance with national priorities. It employs new generation technologies to obtain molecular markers for developing plant genotypes resistant to biotic and abiotic stresses, to identify gene expressions under varying stress conditions with transcriptomic and proteomic approaches, to determine new gene sources involved in stress mechanisms and to characterize them structurally/functionally.
The following is the list of proceedings by scholars from Genetic Engineering and Biotechnology Institute that are published in OMICS International journals and conferences.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi